The Power Behind Precision Antibody Discovery

Realize real business benefits

Geneious Biologics is a next-generation cloud software solution, purpose-built for commercial therapeutic antibody discovery and screening. Delivered through a modern, user-friendly web interface, Geneious Biologics leverages the power of big data to help deliver the life-saving drugs of the future.


The right information at the right time, with a unified, central database, searchable across the organization 


Scale up quickly and efficiently, with additional capacity delivered on demand


Work with and enhance existing systems with an advanced API and a highly configurable system


Innovate faster with large scale computational analysis in the cloud

“Often, you have to shoehorn a software solution into your process; the adaptability of Geneious Biologics was something we liked a lot. Once we knew what we could do with Geneious Biologics, there was no other viable option.”

– Liuhong Chen, Ph.D. Discovery Biology Team Leader at Bicycle Therapeutics

View All Resources

Enhance your workflow

Enterprises involved in therapeutic antibody R&D are choosing Geneious Biologics and Geneious Prime to narrow the search for successful candidates and innovate faster.


Analyze millions of NGS raw antibody sequences in seconds.


Compare NGS data sets, plot germline diversity, and region frequency.


Spot high-level trends in large scale antibody NGS datasets.


Integrate seamlessly with Geneious Prime.

“Geneious Biologics allows us to drill into huge antibody sequence sets and quickly identify where errors lie and inspect bad clones. This will ensure we return the most effective, stable therapeutic antibody candidates to our clients, faster.”

– Daniela Teixeira, COO at FairJourney Biologics

Great minds choose Geneious

“IONTAS had a requirement for processing large quantities of data from both our service based antibody discovery projects and our internal developments. The collaboration has been close and resulted in Geneious Biologics delivering a software solution that has significantly improved the efficiency and scope of our sequence analysis workflows during therapeutic antibody discovery.”

– Peter Slavny, Group Leader at IONTAS